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Abstract
Background: Glioblastoma multiforme is the most malignant cancer of the brain and is notoriously difficult to
treat due to the highly proliferative and infiltrative nature of the cells. Herein, we explored the combination
treatment of pre-established human glioma xenograft using multiple therapeutic genes whereby the gene
expression is regulated by both cell-type and cell cycle-dependent transcriptional regulatory mechanism conferred
by recombinant HSV-1 amplicon vectors.
Results: We demonstrated for the first time that Ki67-positive proliferating primary human glioma cells cultured
from biopsy samples were effectively induced into cell death by the dual-specific function of the pG8-FasL
amplicon vectors. These vectors were relatively stable and exhibited minimal cytotoxicity in vivo. Intracranial
implantation of pre-transduced glioma cells resulted in better survival outcome when compared with viral vectors
inoculated one week post-implantation of tumor cells, indicating that therapeutic efficacy is dependent on the viral
spread and mode of viral vectors administration. We further showed that pG8-FasL amplicon vectors are functional
in the presence of commonly used treatment regimens for human brain cancer. In fact, the combined therapies of
pG8-FasL and pG8-FADD in the presence of temozolomide significantly improved the survival of mice bearing
intracranial high-grade gliomas.
Conclusion: Taken together, our results showed that the glioma-specific and cell cycle-dependent HSV-1 amplicon
vector is potentially useful as an adjuvant therapy to complement the current gene therapy strategy for gliomas.
Background
Glioblastoma multiforme (GBM) accounts for more than
70 % of all primary central nervous system neoplasms in
adults [1]. Despite advances in surgery, chemotherapy,
and radiotherapy, the life expectancy of patients with
GBM is still less than 1 year [2]. The failure of current
therapeutic approaches to treat GBM is attributed to the
high proliferative and infiltrative nature of these neo-
plasms [3]. Malignant cells are often seen surrounding
the neurons and blood vessels and migrate through the
white matter tracts to regions distant from the original
tumor mass, thus the incidence for tumor recurrence is
high. Herein, we explored the combination treatment of
pre-established human glioma xenograft using multiple
therapeutic genes whereby the gene expression is regu-
lated by the status of cellular proliferation of the cancer
cells.
We have previously constructed a Herpes Simplex
Virus type 1 (HSV-1)-based amplicon vector in which
the activation of the transgene expression is regulated
by a G0/G1-specific transcriptional repressor protein
termed cell cycle-dependent factor 1, CDF-1 [4]. CDF-1
repressor protein binds to the CDE/CHR regulatory
region located within the cyclin A promoter. In quies-
cent cells, the transactivation of cyclin A promoter
could not take place due to the binding of the CDF-1
repressor protein onto the cyclin A promoter. However,
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in actively proliferating cells, transcription of the lucifer-
ase reporter [4,5] or therapeutic gene [6] is activated
due to the absence of the CDF-1 repressor protein. As a
proof-of-concept, we have chosen the Fas ligand (FasL)
and the Fas-associated death domain (FADD/MORT1)
as therapeutic genes because it is important that the
effects derived from these genes should not mask the
cell cycle-dependent function of the amplicon viral
vectors.
Fas ligand/APO-1L (CD95L) is a ~ 40 kDa type II
membrane protein belonging to the tumor necrosis fac-
tor (TNF) family. Full length FasL can be further pro-
cessed to release a functional soluble 26 kDa molecule
known as soluble FasL [7]. Binding of FasL to its recep-
tor Fas triggers the trimerization of the Fas receptors
and initiates the recruitment of the cytoplasmic adaptor
protein FADD through the interaction of the death
domains [8]. Recruited FADD then interacts with pro-
caspase-8 via the death effector domain to form the
death-inducing signaling complex (DISC). The close
proximity of caspase-8 zymogens facilitates their autoca-
talytic cleavage, which subsequently trigger the down-
stream effector caspases resulting in apoptosis [7,9].
Both Fas and FasL expression are absent in normal
astrocytes; however, the expression of Fas, but not FasL,
in astrocytomas appear to correlate with neoplasm
grade [10-12]. Based on these findings, the Fas/FasL
receptor system has been proposed as specific target for
human brain tumor therapy. This contradicts another
school of thought where the Fas/FasL receptor interac-
tion grant the tumor cell an immune-privileged status,
supported by studies demonstrating that the FasL
expression in cancer cells deliver death signals to acti-
vated Fas-positive T lymphocytes [13-15]. Aside from
the possible role in immune surveillance, some of the
glioma cells are resistant to Fas-induced apoptosis
[16,17], possibly due to low levels of Fas expression
[16,18], or absence of FADD [19] or caspase 8 expres-
sion [20]. Alternatively, epigenetic aberrations can select
for glioma cells that possess several resistance mechan-
isms to conventional therapies [21]. Interestingly, the
overexpression of caspase 8 or FADD has been demon-
strated to rescue the defect and rendered the cells sen-
sitive to FasL-induced apoptosis [19,22]. Recently,
inducible FADD was also shown to induce apoptosis in
resistant glioma cells [18].
Since the Fas/FasL receptor pathway converges at
FADD, we hypothesized that the overexpression of
FADD could sensitize glioma cells to FasL-induced apop-
tosis. In view of the multifaceted roles of FasL and FADD
in keeping the homeostasis of immune cells, these genes
were inserted into a previously generated cell-cycle regu-
latable HSV-1 amplicon vector under a glial cell-specific
GFAP promoter. We demonstrated that the newly
generated therapeutic vectors are capable of inducing cell
death in proliferating primary human glioma cells
derived from patients, suggesting that these vectors are
functional in a clinical scenario. Furthermore, these vec-
tors are stable, elicit minimal immune response, and are
not significantly hampered by chemotherapy or irradia-
tion in vivo. More importantly, we showed that the
co-expression of FasL and FADD could elicit potent anti-
tumor effect, which was enhanced in the presence of
temozolomide, resulting in prolonged survival of mice
bearing orthotopic gliomas. Taken together, our results
demonstrated that the glial-specific, cell cycle-regulatable
HSV-1 amplicon viral vectors may prove useful in enhan-
cing the efficacy of glioma treatment.
Results
pG8-FasL amplicon viral vectors induced apoptosis in
human glioma cells in a glial cell-specific and cell cycle-
dependent manner
Previously, we reported a HSV-1-based amplicon
viral vector (denoted as pC8-36; Additional file 1)
that mediated luciferase reporter activities in a cell
cycle-dependent manner. These vectors were later
demonstrated to exhibit cell cycle-dependent therapeutic
efficacy when the luciferase reporter gene was substi-
tuted by the FasL gene [6]. To further investigate
whether the therapeutic gene expression can be
restricted not just in dividing cells, but also in glial
fibrillary acidic protein (GFAP)-expressing glial cells, the
ubiquitous CMV promoter in pC8-FasL amplicon vector
(Additional file 1) was swapped with the astrocytes-
specific GFAP enhancer elements and the minimal CMV
promoter. The newly derived vector was named pG8-
FasL (Figure 1A). In rapidly dividing GFAP-expressing
cells, the glial cells-specific promoter is activated result-
ing in the transcription of the Gal4/NF-YA fusion pro-
tein. The fusion protein will transactivate the minimal
cyclin A promoter through its binding to the Gal 4
DNA binding sites, thus mediating FasL protein expres-
sion in proliferating glial cells. The pIH8GalFasL con-
struct, which lacked the Gal4/NF-YA fusion gene,
served as a control vector (Figure 1B). To confirm the
cell-type specific transcription, human glioma cells
ΔGli36 and non-glioma cells, HeLa, were chosen
because they exhibited similar transduction efficiency
when infected by the different types of HSV-1-based
amplicon viral vectors (data not shown). As shown in
Figure 1C, approximately 20 % higher cell death was
observed in proliferating pG8-FasL-transduced ΔGli36
cells in comparison to the G1-arrested cells. On the
other hand, similar levels of apoptosis was detected in
ΔGli36 cells infected with either pIH8GalFasL (Figure
1B) or pG8-FasL under the growth arrest conditions.
This result suggested that the observed cell death is
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non-specific, and most likely due to the combined effect
of low serum and lovastatin that has been shown to
induce apoptosis [23]. By contrast, the pG8-FasL ampli-
con viral vectors appeared to have lost its activities in
HeLa cells, presumably due to the absence of specific
cellular factors that are required for the GFAP-contain-
ing promoter to be functional (Figure 1C, right panel).
These results were in agreement with the higher level of
FasL expression detected in the proliferating ΔGli36
cells (Figure 1D), providing further evidence that the
FasL expression was regulated in a cell cycle-dependent
and glial cell-specific manner.
To demonstrate that pG8-FasL could confer glial cell-
specific transgene expression in vivo, both pG8-FasL and
pC8-FasL amplicon viral vectors were used in mice
bearing xenografts of two different cell type origins. The
latter vector, which consisted of the CMV promoter driv-
ing the Gal4/NF-YA fusion gene, served as positive control
because it has been shown to induce apoptosis in all
proliferating cell type [6]; on the contrary, pC8-36 and
pG8-18 vector (Additional file 1), which expressed the
luciferase reporter protein, served as negative control for
pC8-FasL and pG8-FasL, respectively. The pC8 series of
vectors contained the luciferase reporter gene under the
control of a minimal cyclin A promoter downstream of a
ubiquitous CMV promoter; while the pG8 series of vectors
conferred glioma-specific transgene expression, both vec-
tors conferred cell cycle-dependent transgene expression.
Amplicon viral vectors (i.e., pG8-18, pG8-FasL, pC8-
36, and pC8-FasL; 2 × 106 transduction units (TU))
Figure 1 Glioma-specific and cell cycle-regulated apoptosis mediated by pG8-FasL. (A) The pG8-FasL vector contained three-tandem
repeats of the GFAP enhancer element upstream of the minimal CMV promoter to drive glial-specific activation of the transcriptional activator,
Gal4/NF-YA. The pG8-FasL amplicon vector consisted of the eGFP gene under the control of the immediate early promoter (IE4/5p) for titering
and monitoring of viral infection. (B) pIH8GalFasL was generated by removal of the luciferase gene from pIH8GalLuc (Additional File 1) and
replaced with the FasL gene. This vector lacked the Gal4/NF-YA transactivator sequence, and was used as a negative control throughout this
study. (C) The percentage of apoptotic cells in pG8-FasL and pIH8GalFasL-transduced ΔGli36 and HeLa cells were analyzed 72 h post-infection.
Data shown are the averages of triplicate experiments + SEM. Dotted lines indicate the background apoptosis resulted from the combined effect
of lovastatin and low serum level. (D) FasL expression was determined by ELISA in both ΔGli36 and HeLa cells 72 h post-infection. (E) SCID mice
harboring either ΔGli36-SCID8 or HeLa were injected with 1× 106 TU of pC8-FasL (purple), pC8-36 (blue), pG8-FasL (red), and pG8-18 (black)
vectors. Arrows indicated the repeated injection time. Tumor volume was monitored at different time points.
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were injected into immunodeficient mice harboring
either HeLa-derived or ΔGli36-SCID8-derived tumors.
The latter was used due to its consistency in the induc-
tion of tumor growth in immunodeficient CB-17 SCID
mice. Similar to ΔGli36 cells, this derivative is also sen-
sitive to FasL-induced apoptosis and has more aggres-
sive tumor growth kinetics in immunodeficient mice
(data not shown). Administration of viral vectors was
performed at a 10-day interval based on our previous
findings [6]. Our results demonstrated that pG8-FasL
(red color) effectively suppressed tumor growth in mice
bearing ΔGli36 glioma xenografts when compared with
tumors injected with the pG8-18 amplicon viral vectors
(black; p = 0.007; Figure 1Eleft panel). Similar trend was
not observed in mice bearing HeLa xenografts. At the
final measurement, the tumor volumes in pG8-FasL-
injected ΔGli36 tumors ranged between non-detectable
to 69.06 mm3, whereas the tumor volume in pG8-FasL-
injected HeLa tumors ranged between 282.52 mm3 and
500.09 mm3. In both cell types, tumors injected with
pC8-FasL (purple) were significantly smaller in size
when compared to tumors injected with pC8-36 (blue).
This result demonstrated that the expression of the
FasL gene under the ubiquitous CMV promoter induced
a uniform suppression in the growth of both cell types.
Thus, the cell death mediated by pG8-FasL is restricted
to proliferating tumor cells of glial origin.
Therapeutic efficacy of pG8-FasL amplicon vector on
primary human glioma cells
Since many of the GBM-derived cell lines have been
propagated in the laboratory for an extensive period of
time, we further challenged the clinical application of
our viral vectors by testing their functional abilities in
primary glioma cells that were isolated directly from the
operating theatre. By doing so, we excluded any possible
artifact originating from long-term culture in vitro, and
provided a better evaluation of our viral vectors in a set-
ting that closely resembled the clinical samples in term
of preserving the heterogeneous characteristics of glioma
cell phenotypes. These primary cultures of human
patient-derived glioma cells exhibited constant prolifera-
tion rates for a few passages in vitro as shown by the
positive immunoreactivity with the cellular proliferation
marker, Ki67 (Figure 2A, top panel). They also retained
the glial cell-specific marker, GFAP (Figure 2A; middle
panel), and can be easily infected by the amplicon viral
vectors (MOI of 0.8) as shown by the high percentage
of enhanced green fluorescent protein (eGFP) positive
cells observed (~77%; Figure 2A). FasL expression in the
primary human glioma cells resulted in approximately
30 % cell death (Figure 2B) in pG8-FasL-infected cells
in comparison to those infected with the pG8-18 ampli-
con vector, which was further confirmed in the TUNEL
staining whereby only pG8-FasL-infected cells (eGFP+)
were TUNEL positive (Figure 2C). By contrast, pG8-18
infected cells exhibited minimal cell death (Figure 2B
and 2C). Taken together, we have clearly demonstrated
that the pG8-FasL amplicon viral vectors induced apop-
tosis not only in GBM-derived cell lines but also in pro-
liferating primary human glioma cells.
Next, we investigated whether the therapeutic effi-
cacy mediated by pG8-FasL could be enhanced by
another pro-apoptotic gene such as FADD since the
Fas/FasL receptor pathway converges at FADD. As
shown in Figure 2D, the co-expression of FasL and
FADD resulted in the highest level of cell death
observed. Cell death induced by pG8-FasL and pG8-
FADD was higher than those observed in pG8-18
infected cells by approximately 3.1-fold and 1.8-fold
respectively. The co-expression of FasL and FADD
further increased apoptosis by 2.3-fold and 1-fold rela-
tive to pG8-FADD or pG8-FasL alone, respectively.
Taken together, these results showed that the co-
expression of FasL and FADD synergistically enhanced
apoptosis in primary human glioblastoma cells.
Co-expression of FasL and FADD in vivo prolonged the
survival of orthotopic glioma-bearing mice
Based on the results above, we decided to investigate
whether the synergistic effect of FasL and FADD in
enhancing apoptosis could be recapitulated in vivo. In
Paradigm 1, ΔGli36 human glioma cells were pre-
infected with equal ratios (5×105 TU each) of pG8-FasL
and pG8-FADD amplicon viral vectors followed by
implantation into the right hemisphere of immunodefi-
cient mice on the next day (Figure 3A). The viability of
ΔGli36 cells were confirmed by both trypan blue as well
as TUNEL assays (Additional file 2) prior to intracranial
implantation. In Paradigm 2, equal ratios (5×105 TU
each) of pG8-FasL and pG8-FADD amplicon viral vec-
tors were injected into pre-established ΔGli36 tumors
one week after tumor implantation (Figure 3B). As
expected, co-expression of both FasL and FADD pro-
longed the median survival time of ΔGli36 tumor-bear-
ing mice. For Paradigm 1, the median survival time of
mice were improved by 57 % from 19 days (control
group) to 30 days, with 2 mice surviving past 30 days
but eventually succumbed at days 43 and 49 (p = 0.0081
by log-rank; Figure 3A). By contrast, direct intratumoral
injection of pG8-FasL and pG8-FADD into pre-estab-
lished glioma resulted in a reduced but significant over-
all survival of 37.5% (p = 0.0163 by log-rank; Figure 3B).
PCR analysis confirmed the presence of the amplicon
virions based on the eGFP marker gene. To understand
if the difference observed between the two paradigms
may be due to possible differences in the transduction
efficiency, the percentage of viral vectors infected cells
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(as marked by the presence of eGFP) were examined in
both scenarios. In Paradigm 1, approximately 95 % of
ΔGli36 cells were efficiently infected at an MOI of 2.0
in vitro (Additional file 2). By contrast, direct inocula-
tion of the viral vectors resulted in approximately 17.83
% of the glioma cells positive for eGFP (Figure 3Cii).
The observed difference may be due to the poor spread-
ing of these vectors or that the vectors were inoculated
into region of necrosis or hypoxia that is unfavorable for
infection. Thus, we first determined the extent of the
viral spread by estimating the area covered by eGFP+
cells in representative cryosections. The estimated area
of spread, based on the formula π*r1*r2, (where r1 and
r2 represent radii of the eGFP section; Figure 3Ciii), was
approximately 0.53 mm2, which was less than 0.5% of
an average coronal mouse brain section, indicating that
the limited vector spread resulted in a lower transduc-
tion efficiency. Next, we examined whether these virions
were less stable in the tumor-bearing region of the
mouse brain. To address this issue, similar amount of
viral vectors (1 × 106 TU) was administered into the
normal and glioma-bearing hemisphere of the mouse
brain. At different time points, the brains were removed
and analyzed for the presence of the luciferase gene. As
shown in Figure 3D, luciferase gene was detectable in
both hemispheres up to day 28, indicating the stability
Figure 2 Therapeutic efficacy of pG8-FasL in primary GBM. (A) Images showed the immunostaining against Ki67 (top panel) and GFAP
(middle panel) in primary human glioma cells Bottom panel, primary human glioma cells were infected with MOI of 0.8 of pG8-18. Images
showed the percentage of eGFP+ cells. Original magnification ×100 was shown. (B) The percentage of apoptotic cells in pG8-FasL and pG8-18-
transduced primary glioma cells. Data shown are the averages of triplicate experiments ± SEM. (C) Fluorescence images showed eGFP+ and
TUNEL+ cells on pG8-FasL and pG8-18-transduced primary glioma cells 72 h after infection. Transduction efficiency of primary human glioma
cells as visualized by eGFP expression. Original magnification ×100 was shown. Images were captured using Nikon TE300 wide-field microscope
equipped with a digital color CCD camera. (D) The effect of FasL and FADD expression on primary human glioma cells was examined. The
percentage of cell death in primary glioma cells infected with the various amplicon viral vectors was determined after 72 h. Data shown are
averages of triplicate experiment ± SEM.
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Figure 3 Effect of FasL and FADD expression in human glioma xenograft in vivo. Kaplan-Meier survival analysis of mice receiving (A) ΔGli36
cells preinfected with pG8-FasL and pG8-FADD, (B) intracranial injections of pG8-FasL and pG8-FADD into pre-established ΔGli36 tumor in
comparison to controls (n = 5). PCR analysis performed on Hirt’s DNA isolated from the mouse brain using primers against the exogenous eGFP
gene and normalized using 18S. (C) Flow cytometry analysis of the percentage of eGFP+ cells in mice injected with 1 × 106 TU of (ii) pG8-18
amplicon vectors in comparison to (i) control. (iii), Photomicrograph of brain section showed the spreading of the pG8-18 viral vector. Image
was captured using a 20×/N.A 0.50 Plan Fluor lens mounted on an Axioimager inverted microscope. r1 and r2 are the distance from the center
of the eGFP+ region. The area of dispersion was calculated using the LSM Image browser (Zeiss) based on the formula for ellipse area = π*r1*r2.
(D) PCR analysis performed on Hirt’s DNA isolated from the non-tumor-bearing hemisphere (N) and the tumor-bearing hemisphere (T) of a
mouse brain injected with pG8-18 amplicon viral vectors. PCR was performed using primers specific for luciferase and 18S. (E)
Immunohistochemistry images showing the immunogenicity of pG8-18 amplicon viral vectors (1×106 TU) inoculated into immunocompetent
Balb/c mice. Sections were stained for CD4, CD8 and CD11b on days 1 and 4 post-injection and counterstained with methyl green. Images
shown are original magnification ×200.
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of the amplicon viral vectors in vivo. We did not check
for the presence of the luciferase gene over longer time
point because mice bearing the ΔGli36 glioma xenograft
succumb to brain tumors after 1 month. Although
HSV-1 amplicon viral vectors have been reported in sev-
eral studies to exhibit minimal cytotoxicity due to the
absence of the helper viruses, the presence of exogenous
elements such as the yeast Gal4 protein and the mouse
NF-YA proteins from the pG8-based amplicon viral vec-
tors could potentially generate antigenic peptides that
elicit an immune response from the residual nonspecific
immune system of the nude mice, which may subse-
quently also affect the therapeutic outcome in Paradigm
2. To exclude this possibility, pG8-18 amplicon viral
vectors (1× 106 TU) were intracranially administered
into immunocompetent Balb/C mice. In parallel, similar
volume of PBS was injected into the same region of the
mouse brain in the control mice. All mice were sacri-
ficed either on day 1 or 4 post-viral transduction. The
activation of the immune response was determined by
immunohistochemistry staining for T lymphocytes (CD4
and CD8) and microglia (CD11b) infiltration. CD4, CD8
and CD11b expression were detectable one day post-
injection (Figure 3E) in both PBS and pG8-18-injected
mice, indicating that both PBS and pG8-18 viral vectors
induced inflammatory responses, possibly due to the
transient disruption of the blood brain barrier. However,
immunoreactivity from the three markers was not
detectable at day 4 in neither group of mice, suggesting
that pG8-based viral vectors are also relatively non-
immunogenic. Taken together, these results demon-
strated that the pG8-based viral vector is relatively
stable and non-immunogenic in vivo and that the lower
therapeutic efficacy observed in Paradigm 2 is due to
limited vector spread and mode of vector delivery.
pG8-18 amplicon vector remains functional after
treatment with Temozolomide or g-irradiation
Temozolomide (TMZ) is a monofunctional alkylating
agent with a favorable toxicity that is commonly used in
the treatment of recurrent glioma [24]. Ionizing radia-
tion (IR) therapy has also been adopted as a choice of
treatment for malignant gliomas [25]. Together, they
conferred survival benefit in patients with GBM and
have become part of a new standard of care for GBM
patients [26]. Given that our viral vectors (pG8-18-based
vectors) mediated therapeutic gene expression specifi-
cally in proliferating glial cells, they are best suited as an
adjuvant therapy to kill residual dividing glioma cells
that have not been completely removed during surgery,
radiation or chemotherapy. Thus, we extended our pre-
vious studies to examine the functionality of pG8-18
amplicon vectors in the presence of either treatment.
Human glioma ΔGli36 cells were infected with either
pG8-18 or the control amplicon viral vector pIH8GalLuc
followed by treatment with TMZ. In agreement with
published literature [27], we observed an accumulation
of cells in the G2/M phase (from 24-26 % to 45-51 %) of
the cell cycle when the cells were treated with TMZ
(data not shown). Although we observed a decline in
the luciferase reporter activities in pG8-18-transduced
TMZ-treated cells when compared with the pG8-18-
transduced untreated cells, similar trend was also
observed in cells infected with control pIH8GalLuc vec-
tors (Figure 4A), suggesting that the lower luciferase
activity is probably due to the general cytotoxic effect
seen in most chemotherapy drugs. Importantly, the
overall luciferase activities mediated by pG8-18 is still
significantly higher (511-fold) than TMZ-treated glioma
cells transduced by the control pIH8GalLuc vectors (Fig-
ure 4A). Based on these observations, we concluded that
the amplicon viral vectors are functional in the presence
of TMZ.
Next, we examined whether DNA damaging g-irradia-
tion will lead to the loss of previously characterized cell
cycle-dependent transgene activation conferred by pG8-
18 vectors [4]. To minimize potential virus-specific
interference, we have chosen to transfect the ΔGli36
human glioma cells with pG8-18 amplicon vectors, fol-
lowed by 3 Gy of g-irradiation. As shown in Figure 3B,
significant differences in luciferase activities were not
observed between the untreated and the irradiated cells
transfected with pG8-18, both in the asynchronized and
in the G1-arrested populations. Furthermore, IR did not
severely hamper the cell cycle-regulated luciferase gene
expression mediated by pG8-18; the luciferase expres-
sion was significantly higher in the IR-treated asynchro-
nized cells (82.45 RLU/μg) compared with IR-treated
G1-arrested cells (16.28 RLU/μg) (Figure 4B). Our
results showed that g-irradiation did not negatively
affect the cell cycle-regulated luciferase expression
mediated by the pG8-18 vector. Taken together, these
results confirmed that pG8-18-based amplicon vector
could be used in combination therapies involving TMZ/
IR or both.
To determine whether concurrent treatment of the
therapeutic vectors, pG8-FasL and pG8-FADD, with
TMZ or IR or both could induce an even greater extent
of cell death, ΔGli36 glioma cells were pre-infected with
MOI of 1.0 of pG8-FasL and pG8-FADD amplicon
viruses, followed by treatment with TMZ, IR or both. In
parallel, pG8-18-infected cells were treated the same
way and used as controls. Our results showed that the
percentage of cell death induced by the pG8-18 with
TMZ (24.8 %) or IR (24.7 %) alone was lower in com-
parison to pG8-FasL/FADD amplicon viruses (37.6 %;
Figure 4C). However, when the pG8-FasL/FADD was
introduced together with TMZ and IR, the apoptotic
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activity of pG8-FasL/FADD was significantly enhanced
from 37.6 % (untreated) to 62 % (TMZ), 66 % (IR) and
95.5 % (TMZ/IR), respectively (Figure 4C). These results
showed that TMZ and IR further increased the efficacy
of FasL and FADD in vitro.
Double arm therapy using pG8-FasL/FADD with TMZ
prolonged the survival of glioma-bearing mice
To confirm the observed enhanced efficacy of pG8-FasL
and pG8-FADD in the presence of TMZ and IR in vivo,
the amplicon viruses were administered one week post-
tumor cells implantation subcutaneously. The follow day,
TMZ was given for a period of 5 days at 10 mg/kg/day,
and IR was administered at 2 Gy/day for the same period
of time (Additional file 3). Our results showed that the
pG8-FasL and pG8-FADD amplicon viruses could effec-
tively suppressed the tumor growth for about 1 week
post-injection. However, the anti-tumor effect was lost as
the tumor grew in size, which was anticipated since these
amplicon viruses are defective in replication. Mice trea-
ted with both amplicon viruses and IR resulted in tumors
about 1/4 the size of control alone. Complete tumor
regression was observed in animals injected with pG8-
FasL/FADD followed by combined treatment with TMZ
and IR. So far, the data are in agreement with our earlier
in vitro findings. Contrary to our expectation, the group
of mice treated with pG8-FasL/FADD and TMZ also had
tumors that regressed completely. We attributed the lat-
ter to the high dose of TMZ used that had efficiently
masked the precise therapeutic effect of the amplicon
viruses. Since post-treatment with IR exhibited minimal
effectiveness in this experiment, we decided to focus our
study on evaluating the efficacy of amplicon viruses with
TMZ treatment in a clinical relevant mouse model.
Figure 4 Effect of TMZ and IR on gene expression mediated by pG8-18-based vectors. (A) ΔGli36 cells were infected with either pG8-18 or
pIH8GalLuc vector for 6 h prior to treatment with TMZ. Cells were treated with TMZ for 1 h, after which the cells were replenished with fresh
medium without TMZ and harvested at 48 h post-TMZ treatment for the analysis of luciferase expression. (B) To determine the effect of IR on
the cell cycle-regulated transgene expression, ΔGli36 cells were transfected with either pG8-18 or pIH8GalLuc vector for 6 h prior to 3Gy of
irradiation, after which the cells were replenished with either fresh medium or medium containing lovastatin. Cells were harvested at 48 h post-
transfection for the analysis of luciferase expression. (C) ΔGli36 cells infected with pG8-FasL and pG8-FADD were subjected to 75 μM TMZ, 3 Gy
IR, or combination of TMZ and IR. Percentage of cell death was determined after 72 h. Data shown are % cell death in either pG8-18-infected or
pG8-FasL/FADD-infected cells treated with TMZ, IR or TMZ and IR. For all experiments, data shown are averages of triplicate experiments + SEM
and the total amplicon viruses used was MOI of 1.0.
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Accordingly, pG8-FasL/FADD amplicon viruses were
intracranially administered to mice bearing intracranial
high grade gliomas as depicted in Figure 5. TMZ (5 daily
doses of 5 mg/kg) was administered 8 days post-tumor
implantation. As shown in Figure 5, combination treat-
ment of TMZ with pG8-FasL/FADD significantly pro-
longed the survival of the tumor-bearing mice in
comparison to TMZ or pG8-FasL/FADD alone. On the
other hand, TMZ, as a single agent, was not as effective
as pG8-FasL/FADD in enhancing the survival of tumor
bearing mice, albeit the difference between the median
survival time for both treatment regimens was not statis-
tically significant. Collectively, our results showed that
TMZ can be used in combination with the cell cycle-
regulated vector to markedly improve anti-tumor
response.
Discussion
GBM have retained their dismal prognosis despite
advances in neurosurgical techniques, radiation and drug
therapies. Some of the difficulties encountered include
inaccessibility to resective surgery because of anatomical
location and tumor recurrences. Based on a model that
predict the number of tumor cells distributed around the
primary tumor bed, the percentage of tumor cells found
at a distance more than 2 cm from the tumor edge is
at ~2 % prior to surgery and increased to ~ 23 % post-
surgical resection [28]. Thus, a strategy that can effec-
tively target the highly proliferating tumor cells is
urgently in need. We have previously generated a HSV-1
amplicon viral vectors whereby the transgene expression
is regulated by cell proliferation [4,6]. The present study
aimed to explore the clinical feasibility of this vector in
the treatment of human brain tumors by placing the
FasL or FADD genes under the regulation of a glial cell-
specific promoter. We demonstrated the therapeutic effi-
cacy of these vectors in primary cultures of human brain
tumors, and showed their ability to mediate cell-type
specific transgene expression in vivo. More importantly,
the efficacy of these therapeutic viruses was greatly
enhanced by TMZ, resulting in prolonged survival of
glioma-bearing mice.
The ligands of the TNF family (e.g, FasL, TRAIL and
TNF-a) and the members of the corresponding TNF
receptor superfamily are known to exhibit pleiotrophic
activities in mammalian cells. They can induce cellular
proliferation, differentiation or cell death depending on
the responding cell type and the microenvironment [7],
for e.g., Fas/FasL interaction has been shown to be
involved in neurogenesis [29]; the Fas/FasL system was
also demonstrated to confer immune privileged status to
tumor cells due to the expression of FasL on the tumor
cells and the tumor endothelium [30,31], which induces
cell death in the Fas-expressing T cells. However, how
this process is regulated is still unknown. Despite these
issues, several groups have generated recombinant viral
vectors that deliver the FasL gene to eradicate glioma
cells and have demonstrated prolongation of survival
[32,33]. However, high level of FasL expression has been
shown to induce liver failure [34]. Thus, restricting the
FasL expression to tumor cells is essential if FasL is to be
employed for cancer therapy. We have chosen FasL as
our therapeutic gene because in our cell cycle-dependent
transgene activation system, the therapeutic effect cannot
be overwhelming as this could potentially mask the cell
cycle-regulatory property of the vectors. To circumvent
the possible complications of the immune system, we
have chosen the immunodeficient nude mice as our
mouse model; hence, the FasL-induced apoptosis could
still serve as a good tool to assess the therapeutic efficacy
of our dual-function viral vectors.
Many clinical trials in human brain tumors are con-
ducted by injecting recombinant viral vectors into the
tumor cavity margins following surgical resection [35].
It is therefore important that (i) the tumor cells are sus-
ceptible to viral infection; (ii) the viruses are stable
Figure 5 Effect of TMZ on FasL and FADD-mediated tumor
regression in intracranial glioma model. Kaplan-Meier survival
analysis of mice receiving ΔGli36 human glioma cells treated with
pG8-FasL and pG8-FADD in combination with TMZ. Animals were
treated on day 7 post-tumor implantation with 2×105 TU (MOI 1.0)
of either pG8-FasL and pG8-FADD or pG8-18 injected i.t. followed by
i.p. delivery of TMZ (5 mg/kg bodyweight) after 18 h. N = 8. Log
rank test, p < 0.05.
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without causing adverse cytotoxic effects; and (iii) the
transgene expression is restricted to only tumor cells.
We have demonstrated that transduction efficiency of
pG8-18 amplicon viruses was relatively high in prolifer-
ating GFAP-positive primary human glioma cells. How-
ever, the transduction efficiency of HSV-1 amplicon
viral vectors has been reported to vary in different pri-
mary glioma cell cultures, possibly due to the heteroge-
neity of the glioma cells and the variation in the cell
surface receptors required for viral entry [36]. Thus, it
may be necessary to pre-examine the efficiency of infec-
tion on a patient’s tumor sample. We have also demon-
strated that the amplicon viruses are relatively stable
(Figure 3D) although the transgene expression mediated
by these vectors maybe transient due to the increasing
tumor cells to vector ratio. The GFAP enhancer
sequence has been shown to confer glial-cell specificity
to T98 [37], ΔGli36, U251 and SF767 [4]. Because the
GFAP enhancer elements drive FasL and FADD expres-
sion specifically in glial cells, the packaging efficiency of
the virions was unaffected (data not shown). Further-
more, FasL expression mediated by pG8-FasL vectors
was higher in proliferating versus growth arrested
ΔGli36 human glioma cells (Figure 2B), which corre-
lated with the enhanced apoptosis observed in the pro-
liferating GFAP-positive ΔGli36 cells (Figure 2A). By
contrast, FasL expression did not differ in the proliferat-
ing HeLa cells versus the G1-arrested cells (Figure 1D),
indicating that the transgene expression mediated by
pG8-FasL is regulated by type of cells under proliferat-
ing conditions. This is further supported by similar find-
ing in vivo (Figure 1E).
One of the major obstacles encountered in targeting
death receptors in tumor cells is that the cells are
usually resistant to apoptosis induced by death receptor
ligands [17,38]. A recent report has shown that CD133-
positive cells isolated from human glioma cells are also
resistant to Fas-induced apoptosis [39]. Likewise, cells
derived from human patients have been shown to be
resistant to etoposide, paclitaxel, TMZ and carboplatin
[40]. These findings suggest that the immature stem
cells in glioma could be an important factor of resis-
tance to Fas signaling pathway. Thus, enhanced thera-
peutic efficacy is much desired. The co-expression of
FADD and caspase-8 are reported to be required for the
synergistic cytotoxicity induced by combined IR/TRAIL
treatment [41]. As such, we explored whether the thera-
peutic efficacy of pG8-FasL could be improved in the
presence of FADD. Our results showed that the co-
expression of FasL and FADD in primary glioma cells
enhanced apoptosis by 20% in vitro (Figure 2D) and
prolonged the survival of intracranial glioma bearing
mice (Figure 3A and 3B). However, the therapeutic effi-
cacy varies depending on whether the viruses were used
to infect human glioma cells prior to tumor cell implan-
tation (Paradigm 1) or after the establishment of the
tumor mass (Paradigm 2). In both scenarios, signifi-
cantly prolonged survival was observed in mice treated
with amplicon viruses albeit paradigm2 was substantially
less effective. The latter was attributed to the limited
vector spread and mode of vector delivery but not due
to the instability of the amplicon virions (Figure 3A, B
and 3D) or possible immunocytotoxicity elicited by the
vectors (Figure 3E). In fact, Suzuki et al. has reported
the persistent transgene expression conferred by HSV-1
amplicon vectors in the brains of immunocompetent
C57BL/6 mice (up to 385 days post viral injection)
through the incorporation of the Epstein Barr Virus
(EBV) episomal elements [42].
TMZ in combination with IR are currently the first-
line treatment for recurrent GBM and when used con-
currently, have been shown to improve the median
survival time of glioma patients for up to 5 years of fol-
low-up [43]. With that in mind, we investigated whether
TMZ and IR can improve the overall cell death induced
by pG8-FasL and pG8-FADD amplicon viruses. Indeed,
combination treatment of ΔGli36 cells with pG8-FasL/
FADD amplicon viral vectors, TMZ and IR markedly
enhanced the percentage of cell death by ~ 40 % (Figure
4C). We further challenged the effectiveness of TMZ
and IR in vivo (Additional file 3). This time, the sup-
pressive effect of the therapeutic amplicon viruses was
not as remarkable as shown previously (Figure 1E), pos-
sibly due to the lower dose of viruses used, a different
derivative of glioma cells used and a different strain of
mice (SCID mice versus nude mice). Despite these vari-
able parameters, pG8-FasL/FADD amplicon viruses can
still mediate a suppressive effect on the tumor growth.
Irradiation, however, did not significantly enhance the
overall therapeutic efficacy mediated by the pG8-FasL/
FADD viruses (Additional file 3). This is similar to a
report by Yamini et al in that IR alone with adenovirus-
delivered tumor necrosis factor (TNF) did not improve
the survival of glioma-bearing mice [44]. Since the con-
comitant and adjuvant dosage of TMZ and IR with
pG8-FasL/FADD is difficult to manipulate in vivo, we
decide to focus our study on the effect of TMZ and
pG8-FasL/FADD in mice bearing intracranial gliomas,
which are of more clinical relevance. Our results showed
that adjuvant TMZ boosted the therapeutic efficacy of
pG8-FasL/FADD; the survival time was markedly pro-
longed in comparison to mice receiving either TMZ or
pG8-FasL/FADD viruses alone (Figure 5).
The effectiveness of TMZ is largely determined by the
status and expression level of the O6-methylguanine-
DNA methyltransferase (MGMT) [45]. Silencing of the
MGMT promoter has been shown to confer therapeutic
benefits by inhibiting DNA repair upon DNA damage
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induced by TMZ [46]. Moreover, Hegi et al showed that
the patients with methylated MGMT promoter has bet-
ter survival than those without after TMZ and IR treat-
ment [47]. Therefore, we speculated that an even
greater therapeutic efficacy of pG8-FasL/FADD and
TMZ could be achieved in human glioma cells with
generally low MGMT activity. Alternatively, a greater
effect may be seen by increasing the viral dosages, or
using a more potent therapeutic gene such as the cas-
pase-8 or bacterial exotoxin. Caspase-8 is frequently lost
or silenced in human gliomas [20]. Inducible caspase-8
has been shown to be effective in prostate cancer gene
therapy [48] and malignant brain tumors [49]. A fusion
protein consisting of interleukin 13 (IL-13) and a
mutated form of Pseudomonas exotoxin (IL-13-PE) has
also been shown to induce potent and specific cytotoxi-
city in glioma cells that overexpresses the receptor for
IL-13, IL13 receptor-a2 (IL13-Ra2) [50]. Since our cell
cycle-regulatable HSV-1 amplicon viral vectors have
been shown to confer relatively tight regulation of gene
expression, it will be interesting to study the potential
efficacy in these settings.
From a clinical application point of view, there are
two ways one could use these vectors as gene delivery
vehicles. They can either be used directly to infect cells
surrounding the margins of tumor resection followed by
adjuvant/concurrent treatment with TMZ and/or IR, or
to infect ex-vivo cultured adult human mesenchymal
stem cells (MSC), which has been shown to be resistant
to chemotherapy drugs such as cisplatin, vincristine, and
etoposide [51] and IR [52]. Although the latter strategy
needs to be stringently evaluated, the inherent tumor
tracking properties of MSC is extremely attractive espe-
cially since the incidence of metastatic brain tumors
with high proliferative potential is predicted to increase
[53]. We have performed independent studies to show
that HSV-1 amplicon viral vectors can infect MSC effi-
ciently without affecting the cellular proliferation, tumor
homing and multilineage differentiation potential of
MSC [54]. Thus, further studies are required to couple
the homing potential of MSC with the cell cycle-regula-
table HSV-1 amplicon vectors.
In summary, we have demonstrated the therapeutic
efficacies of pG8-FasL/FADD amplicon viruses in
human glioma cells derived from established cell lines
and patients biopsy samples. The vectors are relatively
stable with minimal cytotoxicity and remained func-
tional in the presence of chemotherapy and ionizing
radiation treatment. More importantly, combined treat-
ments of these therapeutic viruses with TMZ prolonged
the survival of intracranial glioma-bearing mice. Given
that gliomas are heterogeneous in nature, the combina-
tion of TMZ and our cell cycle-regulated FasL and
FADD vector should confer added survival benefits.
Conclusion
We have previously constructed a HSV-1 amplicon viral
vector in which the transgene expression is regulated by
cellular proliferation. In the present study, we demon-
strated that Ki67-positive proliferating primary human
glioma cells cultured from biopsy samples were effec-
tively induced into cell death by the dual-specific func-
tion of pG8-FasL amplicon vectors. These vectors are
cell-type specific in addition to their ability to confer
cell cycle-dependent transgene expression. Their effica-
cies are not hampered by the presence of chemotherapy
or irradiation, and are relatively stable and non-cytotoxic
in vivo. Most importantly, the combined therapies of
pG8-FasL and pG8-FADD in the presence of TMZ sig-
nificantly improved the survival of mice bearing intra-
cranial high-grade gliomas. In summary, these amplicon
viral vectors are potentially useful as adjuvant therapy to
complement the current therapeutic regimens for
human gliomas.
Materials and methods
Isolation of primary human glioma cells
This study has been approved by the SingHealth Centra-
lized Institutional Review Board, Singapore. Primary
human glioma cells were isolated, after informed consent,
from the brain tumor tissues of patients undergoing brain
tumor surgery at the National Neuroscience Institute,
Singapore. The harvested tissue was separated into small
pieces in the presence of complete medium (Astrocyte
Basal Medium (ABM) supplemented with 10% FBS, Peni-
cillin/Streptomycin, normocin and L-Glucose; Cambrex
Bio Science Walkersville, Inc., Walkersville, MD). The
tissue suspensions were first passed through a 5 ml sero-
logical pipette, followed by a 1 ml pipette and finally a
flame-polished pasteur pipette until no clumps were visi-
ble. Following trypsin digestion, the homogenate was fil-
tered through a 70-μm cell strainer (BD Biosciences, San
Jose CA), and then subjected to centrifugation. The col-
lected cells were cultured in complete ABM. All cells
were maintained at 37°C in a humidified incubator with
5% CO2. The culture of ΔGli36 and HeLa cells was per-
formed as described previously [6].
Plasmid constructions
The construction of pG8-18, pIH8GalLuc, pC8-36, pC8-
FasL, and pIH8GalFasL plasmid were described pre-
viously [4,6]. To generate pG8-FasL, the entire DNA
fragment encoding the Gal4/NF-YA fusion protein and
the 8GalFasL region from pC8-FasL vector [6] was
excised using PmeI and inserted into the same restric-
tion enzyme site on pG8-18. A similar subcloning strat-
egy was used for the construction of pG8-FADD from
pC8-FADD [6]. All plasmids were amplified in E. coli
STBL-2 (Invitrogen, Grand Island, NY) and the DNA
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was extracted using a QIAprep Spin Miniprep kit (Qia-
gen GmbH, Hilden, Germany) and verified by DNA
sequencing (Applied Biosystem Inc., USA).
Synchronization of cells for cell cycle analysis
Synchronization of cells in the G1 phase of the cell cycle
was performed by treating the cells with 40-60 μM of
lovastatin (Merck, Singapore) in the presence of 0.1%
FBS for 48 h. Cell cycle analysis was performed as
described previously [4].
Packaging of helper virus free HSV-1 amplicon viral
vectors
Packaging of the HSV-1 amplicon vector was performed
as described previously using the helper virus-free packa-
ging method [55]. The titer obtained for the resulting
packaged amplicon viral vectors ranged from 1×107 to
1×108 TU/ml after concentration through a sucrose gra-
dient. Infection of viral vectors on ΔGli36 and HeLa cells
were performed at a multiplicity of infection (MOI) of
1.0 and the transduction efficiency was determined by
flow cytometry for the presence of eGFP+ cells.
Immunohistochemistry, immunofluorescence and TUNEL
staining
Immunohistochemistry and immunofluorescence staining
were performed as previously described [4]. Antibodies
(GFAP, Ki67, CD4, CD8, and CD11b) were purchased
from BD Biosciences and used at 2 μg/ml concentration.
TUNEL staining was performed using the In situ cell
death detection kit (Roche) according to manufacturer’s
instruction. Briefly, fixed cells were permeabilized with
0.1% triton in 0.1% sodium citrate solution prior to incu-
bating in solution containing the terminal deoxynucleoti-
dyl transferase enzyme and nucleotide mixture. Staining of
cells was carried out at 37°C for 1 h. After which, non-
specific staining was removed by rinsing the cells in PBS
twice. Samples were then visualized under fluorescence
microscope. All images were either acquired on the CCD
digital camera (Olympus DP11, Olympus, Japan) mounted
on the upright microscope (Olympus BX41) or the Nikon
TE300 Eclipse fluorescence microscope (Nikon, Japan).
Treatment with TMZ and g-irradiation
Temozolomide (Temodal; Schering Plough, Belgium)
was dissolved in DMSO (Sigma Aldrich) to produce a
100 mM stock solution for in vitro experiments. For
in vitro experiments, TMZ was diluted with PBS to
obtaine 75 μM solutions. For in vivo experiments, stock
solution was diluted in PBS to a final concentration of
5 mg/ml. A dose of 5 mg/kg body weight was used,
which is equivalent to half of the recommended dosage
of 25 mg/kg/m2 in adult humans [56].
To assess the effect of TMZ treatment on luciferase
gene expression, cells were first infected with the
respective amplicon viral vectors for 6 h. The trans-
duced cells were divided into two groups, one portion
of the cells were cultured in complete medium, while
the other portion was treated with 75 μM of TMZ at
37°C. After 1 h of treatment, the cells were rinsed twice
with PBS and replenished with complete medium con-
taining 10% serum. To assess the effect of IR, similar
procedure was performed as treatment with TMZ,
except that the cells were transfected with pG8-18 or
pIH8GalLuc plasmid. Transfected cells were exposed to
3 Gy of g-irradiation, followed by incubating the cells in
either fresh complete medium or medium containing
lovastatin. Luciferase activities were measured after 48 h
of transfection.
To assess the effect of TMZ and IR on pG8-FasL/
FADD-mediated cell death, ΔGli36 cells was infected
with MOI of 1.0 of pG8-FasL and pG8-FADD or pG8-
18 amplicon viruses. The viral supernatant was removed
after 6 h and cells were cultured in medium containing
75 μM of TMZ. The cells were subsequently subjected
to 3Gy of IR treatment. TMZ-containing medium was
removed after 1 h of incubation. The percentage of cell
death was assessed after 72 h by trypan blue exclusion
assay.
Animal Experiments
All animal experiments were performed according to the
guidelines and protocols approved by the SingHealth Insti-
tutional Animal Care and Use Committee, Singapore.
To determine the efficacy of FasL in vivo, 6-8 weeks
old CB-17 SCID mice (Animal Resource Centre, Austra-
lia), inoculated with either HeLa or ΔGli36-SCID8 cells
(2 × 106) at their right flank, were divided into 4 groups.
One day following tumor inoculation, 2 × 106 TU of
viral vector was administered intratumorally. Injections
of viral vectors were repeated every 10 days until tumor
necrosis was observed in the non-treated groups. The
tumor volume was measured and calculated according
to the formula volume = 0.52 × length × width2. At the
end of the experimental period, all animals were sacri-
ficed and tumor nodules were harvested. Analysis of
FasL expression was also performed as described pre-
viously [6].
To determine the synergistic effect of FasL and FADD
in intracranial tumor-bearing mice, two experimental
paradigms were designed. In Paradigm 1, ΔGli36 human
glioma cells (1×106) were pre-infected with equal ratios
(5×105 TU each) of pG8-FasL and pG8-FADD amplicon
viral vectors followed by implantation into the right
hemisphere (bregma (0,0) lateral 2.0 mm and depth
2.5 mm) of immunodeficient nude mice on the next
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day. For Paradigm 2, mice were inoculated with ΔGli36
intracranially followed by inoculation of amplicon viral
vectors (MOI of 1.0) intratumorally 7 days later. Mice
were monitored weekly for changes in body weight.
For investigating the combined therapeutic effect of
TMZ with pG8-FasL and pG8-FADD in vivo, immuno-
incompetent nude mice were first inoculated with 2×105
ΔGli36 cells intracranially. Amplicon viruses, either pG8-
18 (2×105 TU) or pG8-FasL and pG8-FADD (MOI of 1.0,
1×105 TU each), were injected intratumorally (i.t.) into the
same co-ordinates after 1 week. TMZ was administered
after 18 h and on a daily basis for 5 days (5 mg/kg which
total to 25 mg/kg) via an intraperitoneal (i.p.) route.
To assess the effect of TMZ and/or IR on FasL and
FADD-mediated tumor regression in a subcutaneous
glioma model, mice bearing ΔGli36 human glioma
xenograft (5×105) at their hind limbs were randomized
into groups indicated in Additional File 3. One week
post tumor cell implantation, pG8-FasL and pG8-FADD
amplicon viruses (combined MOI = 1) were injected
intratumorally (i.t). Treatment with TMZ, IR or TMZ
and IR was initiated 18 h post-virus inoculation. TMZ
was delivered i.p. at a dose of 10 mg/kg/day for 5 doses,
and IR (2Gy/day) was given to the mice, which amount
to a total of 10 Gy. Tumor volume was measured every
3-4 days as detailed above.
To determine the stability of the pG8-18 amplicon
viral vectors in vivo, 1×106 TU of pG8-18 vector was
injected into the left (control) and right hemisphere of
the same immunodeficient nude mice. The right hemi-
sphere consisted of tumor mass (1 × 106 ΔGli36), which
was implanted a week before viral injection. The brains
were then harvested on days 4, 10, and 28 post-injection
and prepared for extraction of viral DNA. Viral DNA
was recovered from brain tissues using Hirt’s method
[57] with slight modifications. Briefly, the tissues were
first frozen with liquid nitrogen and ground into powder
using a mortar and pestle. After that, the tissues were
incubated in 500 μL of lysis buffer (0.6 % SDS, 10 mM
EDTA, pH 8.0, 10 mM Tris-HCl, pH 7.5) for 20 min at
room temperature followed by addition of 125 μl of 5
M NaCl and incubated at 4°C overnight. The next day,
the extract was subjected to centrifugation at 13 000 × g
at 4°C for 30 min. The supernatant was recovered and
extracted with phenol, phenol-chloroform and chloro-
form. The DNA was precipitated using isopropanol,
rinsed with 70% ethanol, and dissolved in 35 μl of TE
(10 mM Tris-Cl pH8.0, 1 mM EDTA) buffer.
To determine the transduction efficiency of pG8-18
amplicon viral vectors, immunodeficient nude mice were
separated into 2 groups and inoculated with 10 μl of
pG8-18 (1 × 106 TU) viral vector. The mouse brains were
harvested 1 day post-injection. On the day of harvesting,
the mice were first perfused through the heart with PBS,
and the brains were harvested and processed to single
cell suspensions. The brains were homogenized in a 50
ml falcon tube with 12 ml of HBSS (Invitrogen) using a 5
ml serological pipette, followed by a 1 ml serological pip-
ette and a flamed-polished Pasteur pipette, until no
clumps were visible. Cells were trypsinized and incubated
for 15 min at 37°C, with mixing every 5 min. The homo-
genates were then filtered through a 70-μm pore size
nylon cell strainer (BD Biosciences), and the filtrates
were subjected to centrifugation at 500 rpm for 15 min at
4°C (without brake) (Beckman Coulter). The supernatant
was removed and the cell pellet resuspended in DMEM
containing 10% serum. The percentage of eGFP+ cells
was analyzed using FACS. For the other group of mice,
the brains were fixed in 4 % PFA solution overnight, fol-
lowed by 30 % sucrose for 48 h, and then sliced into 10-
micron sections. The eGFP+ cells were visualized using a
LSM 510 Meta confocal microscope (Carl Zeiss Micro-
scopy, Göttingen, Germany) with the appropriate filters.
To determine the immunogenicity of the HSV-1
amplicon viruses, immunocompetent Balb/c mice (6
weeks old) was inoculated with either saline or pG8-18
viruses (1×104 TU) in the right hemisphere of the
mouse brain. Brains were harvested on day 1 and 4
post-injections. On the day of harvesting, mice were
perfused through the heart with PBS followed by 4%
paraformaldehyde. Brains were processed and cryosec-
tioned at 10-micron thickness. Immunohistochemical
staining was performed on consecutive sections.
Statistical analysis
The data are presented throughout this study as means
± standard error of the mean. The statistical significance
was evaluated by an unpaired t-test, and p < 0.05 was
considered significant. Kaplan-Meier survival analysis
was used to calculate the percentage of survival as a
function of time, and the survival curves were compared
using the log-rank test.
Additional material
Additional file 1: Schematic diagram of vectors used. (A) The pC8-36
vector contained the CMV promoter driving the Gal4/NF-YA transactivator
in place of the GFAP enhancer element in pG8-18. (B) pC8-FasL was
generated by removal of the luciferase gene from pC8-36 and replaced
with the FasL gene. (C) The pG8-18 vector contained three-tandem
repeats of the GFAP enhancer element upstream of the minimal CMV
promoter. The pG8-18 amplicon vector consisted of the eGFP gene
under the control of the immediate early promoter (IE4/5p) for titering
and monitoring of viral infection. pG8-FADD was generated by swapping
the luciferase transgene in pG8-18 with the FADD gene. (D) pIH8GalLuc,
which lacked the Gal4/NF-YA transactivator sequence, served as a
negative control throughout this study.
Additional file 2: Viability and transduction efficiency of ΔGli36 cells
prior to implantation. (A) TUNEL assay was performed on pre-infected
cells to confirm the viability of the cells prior to intracranial inoculation.
(B) The transduction efficiency of ΔGli36 cells pre-infected with pG8-FasL
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and pG8-FADD prior to tumor implantation was determined by FACS
analysis. Image shown was pseudocolored. Flow cytometry image of
infected cells (red) was superimposed on to the image of uninfected
cells (green).
Additional file 3: Effect of TMZ and IR on FasL and FADD-mediated
tumor regression. The effect of TMZ and/or IR on FasL and FADD-
mediated tumor regression was examined in a subcutaneous glioma
model. Mice bearing ΔGli36 human glioma xenograft (5×105) at their
hind limbs were randomized into groups indicated and injected with
MOI of 1.0 of pG8-FasL/FADD amplicon viruses (i.t.) one week post-tumor
cells implantation. Treatment with TMZ, IR or both was initiated 18 h
post-virus inoculation. TMZ was delivered i.p. at a dose of 10 mg/kg for 5
doses, and IR (2Gy) was given to the mice daily to a total of 10 Gy.
Tumor volume was measured every 3-4 days. Arrow indicated viral
inoculation.
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